New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareAHK-Cu vs Semaglutide

AHK-Cu vs Semaglutide

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticAnti-Aging & Longevity
AHK-Cu
GLP-1 / Weight Loss Agonists
Semaglutide
Summary
AHK-Cu is a copper tripeptide composed of alanine, histidine, and lysine chelated to copper. Distinct from GHK-Cu, AHK-Cu exhibits strong affinity for hair follicle receptors and demonstrates potent hair growth stimulation alongside wound healing and skin regeneration properties.
Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed for type 2 diabetes that has proven remarkably effective for weight loss. Clinical trials show average 15–20% body weight reduction. It is marketed as Ozempic (diabetes) and Wegovy (weight management).
Half-Life
Hours (topical, variable by formulation)
~7 days
Admin Route
Topical, Scalp application, Subcutaneous (research)
SubQ, Oral
Research
Typical Dose
0.01–0.1% concentration
0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg
Frequency
Once or twice daily
Once weekly, subcutaneous
Key Benefits
  • Stimulates hair follicle growth and reduces shedding
  • Increases dermal papilla cell proliferation
  • Promotes wound healing and skin regeneration
  • Antioxidant protection via superoxide dismutase activation
  • Improves skin elasticity and firmness
  • Supports collagen and elastin production
  • Average 15–20% body weight reduction in clinical trials (STEP trials)
  • Significant reduction in appetite and food cravings
  • Improvement in blood sugar control and insulin sensitivity
  • Reduces cardiovascular risk (SELECT trial: 20% reduction in MACE)
  • May reduce risk of kidney disease
  • Improves metabolic markers (cholesterol, blood pressure)
  • FDA-approved — extensively studied with robust safety data
  • Weekly dosing convenience
Side Effects
  • Generally well-tolerated topically
  • Mild scalp irritation or redness in sensitive individuals
  • Possible temporary hair shedding phase at treatment initiation
  • Copper accumulation with excessive systemic use (rare)
  • Nausea (most common, especially during titration)
  • Vomiting
  • Diarrhea or constipation
  • Abdominal discomfort
  • +4 more
Stacks With